Fig. 4From: Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studiesCumulative maintained ≥ 50% response: percentages of patients with chronic migraine who reached ≥ 50% response at or before each month and all subsequent monthsBack to article page